Decreased CD5+ B Cells in Active ANCA Vasculitis and Relapse after Rituximab | Zendy

Donna O. Bunch | Zendy; JulieAnne G. McGregor | Zendy; Nirmal B. Khandoobhai | Zendy; Lydia T. Aybar | Zendy; Madelyn Burkart | Zendy; Yichun Hu | Zendy; Susan L. Hogan | Zendy; Caroline J. Poulton | Zendy; Elisabeth A. Berg | Zendy; Ronald J. Falk | Zendy; Patrick H. Nachman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Decreased CD5+ B Cells in Active ANCA Vasculitis and Relapse after Rituximab

Author(s) -

Donna O. Bunch,

JulieAnne G. McGregor,

Nirmal B. Khandoobhai,

Lydia T. Aybar,

Madelyn Burkart,

Yichun Hu,

Susan L. Hogan,

Caroline J. Poulton,

Elisabeth A. Berg,

Ronald J. Falk,

Patrick H. Nachman

Publication year - 2013

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.03950412

Subject(s) - rituximab , medicine , immunosuppression , cd5 , immunology , b cell , maintenance therapy , vasculitis , gastroenterology , disease , antibody , chemotherapy

B cell significance in ANCA disease pathogenesis is underscored by the finding that ANCA alone can cause disease in mouse models and by the effectiveness of rituximab as therapy in ANCA-small vessel vasculitis (ANCA-SVV). To avoid infections and adverse events from therapy, clinicians require improved markers of disease activity and impending relapse to guide immunosuppression strategies after rituximab treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research